ライフサイエンスコーパス: LVMI

1 LVMI assessed with MRI was a better predictor of the com

2 LVMI decreased unrelated to HR at baseline (p for intera

3 LVMI was measured by echocardiogram at baseline and at 1

4 LVMI, EF and their combination mediated the observed dif

5 is, the RI variability was explained by age, LVMI, and serum phosphate concentration.

6 (LVMI) values, but on multivariate analysis, LVMI correlated with plasma renin activity (p < 0.001) a

7 Utilizing ROC analysis, LVMI was found to be a stronger predictor for adverse ou

8 h smaller LVM (beta: -3.483, P < 0.0001) and LVMI (beta: -0.815, P < 0.0001).

9 hat in late diastole [A wave]) (P = .03) and LVMI (P = .04).

10 ciation was detected between aldosterone and LVMI in males (beta=0.009 [95% CI, 0.001-0.017]; P=0.027

11 at both ages, and aortic distensibility and LVMI were measured by cardiac magnetic resonance imaging

12 ecreased compared with the control group and LVMI was markedly improved by BSJYD treatment in a dose-

13 GT and LVMI could characterize patients as having a normal LV m

14 icant quadratic relationship between Hct and LVMI in premenopausal women (p < 0.01).

15 The mean Hct and LVMI were 46.5% and 41.9%, and 127.3 and 95.8 g/m, respe

16 ference between groups for change in LVM and LVMI was -3.89 g (95% confidence interval: -1.1 to -6.7)

17 nterrelationsh between kidney morphology and LVMI indicates that such associations may be a biologica

18 ) and between aldosterone-to-renin ratio and LVMI in females (beta=0.098 [95% CI, 0.001-0.196]; P=0.0

19 ne-to-renin ratio and arterial stiffness and LVMI.

20 LVM indexed to body surface area (LVMI) and MWT were significantly higher at TTE compared

21 y than atenolol with adjustment for baseline LVMI and blood pressure and in-treatment pressure (-21.7

22 ADC (Spearman = 0.450, p < 0.05) and between LVMI and ECV (Spearman = 0.181, p < 0.05).

23 Positive associations were noted between LVMI and ADC (Spearman = 0.450, p < 0.05) and between LV

24 uding baseline differences in LVMI, and both LVMI and LA volume conferred additional prognostic infor

25 s significantly more effective in decreasing LVMI (P < 0.01).

26 d in 13% and 30%, respectively, and elevated LVMI was detected in 33%.

27 Interobserver agreement for LVMI and MWT was higher for MRI (intraclass correlation

28 Greater LVMI reduction with losartan was observed in women and m

29 th left ventricular mass (indexed to height; LVMI) in early adulthood with data from the UK Avon Long

30 Low EF and high LVMI were significantly associated with subsequent CVD i

31 SE]: 1.48) and 3.92 (SE: 2.14) g/m(2) higher LVMI, respectively.

32 ociated with lower E/A (P < .001) and higher LVMI (P = .03), indicating restricted diastolic function

33 in men and a small but significantly higher LVMI in men and postmenopausal women.

34 This was associated with higher LVMI in COA (109+/-35 versus 93+/-32, g/m(2); P<0.001).

35 sence of diabetes was associated with higher LVMI.

36 Changes in LVMI measured by cardiovascular MR (n=38) were consisten

37 There were no significant changes in LVMI, CRP, or erythropoietin resistance index in the con

38 lysis patients experienced a 30% decrease in LVMI (154 +/- 33 to 108 +/- 25; P < 0.0001).

39 .12, P = 0.04) predicted a 12-mo decrease in LVMI.

40 ly) largely accounted for the differences in LVMI and C-reactive protein levels across cohorts.

41 enuated by including baseline differences in LVMI, and both LVMI and LA volume conferred additional p

42 tween groups included a 1.3-g/m2 increase in LVMI (95% CI, -0.15 to 2.74; P = .08) and a -0.15 decrea

43 was predictive of longitudinal increases in LVMI (r=0.43, P<0.001).

44 n-based therapy induced greater reduction in LVMI from baseline to the last available study than aten

45 vidual BP variance was predicted to increase LVMI by 0.21%, 95% credible interval: -0.23, 0.69), but

46 aller LV and larger LA volumes and increased LVMI.

47 o -1.3 +/- 4.48 g; p = 0.007) and LVM index (LVMI) (allopurinol -2.2 +/- 2.78 g/m(2) vs. placebo -0.5

48 left ventricular mass (LVM), and LVM index (LVMI) increased in subsequent RI quartile subgroups.

49 ng definition for BA-CCM: (1) LV mass index (LVMI) >=95 g/m(2.7) or (2) relative wall thickness of LV

50 6) and a higher left ventricular mass index (LVMI) (77 +/- 16 vs 70 +/- 13; P = .04).

51 ization for heart failure was LV mass index (LVMI) (hazard ratio (HR)[95% confidence interval] 1.16[1

52 rics or visual grades and the LV mass index (LVMI) (indexed to body surface area on echocardiography,

53 KD-JAC participants, the mean LV mass index (LVMI) and ejection fraction (EF) were 55.7 and 46.6 g/m(

54 ) BP control on left ventricular mass index (LVMI) and kidney function in 75 hypertensive ADPKD patie

55 ocrit (Hct) and left ventricular mass index (LVMI) and LV hypertrophy (LVH) in subjects without known

56 umes and higher left ventricular mass index (LVMI) and LV mass/LV volume ratio.

57 l stiffness and left ventricular mass index (LVMI) before the onset of overt disease.

58 d and increased left ventricular mass index (LVMI) compared with controls, and that Doppler-derived a

59 Left ventricular mass index (LVMI) correlated to the same extent with central and per

60 In all SBP tertiles, LV mass index (LVMI) decreased similarly (LVMI -6.3 +/- 2.2 g/m(2.7), -

61 sociations with left ventricular mass index (LVMI) in untreated persons.

62 e was change in left ventricular mass index (LVMI) measured by transthoracic echocardiography and, in

63 des 1 to 3, and left ventricular mass index (LVMI) tertiles, with steeper gradients in low-biomarker/

64 nts had greater left ventricular mass index (LVMI) values, but on multivariate analysis, LVMI correla

65 pathology, and left ventricular mass index (LVMI) were measured.

66 r =1 follow-up measurement of LV mass index (LVMI) were used in an intention-to-treat analysis.

67 We measured left ventricular mass index (LVMI) with cardiac magnetic resonance imaging (MRI), ass

68 used to measure left ventricular mass index (LVMI), cardiac index (CI), and stroke volume index (SVI)

69 thickness, LV mass (LVM), and LV mass index (LVMI), compared to participants in 7-9 h/night or >9 h/n

70 s defined using left ventricular mass index (LVMI), LV global longitudinal strain (LVGLS) and LV end-

71 hocardiographic left ventricular mass index (LVMI), serum C-reactive protein (CRP), serum calcium and

72 sclerosis), and left ventricular mass index (LVMI; indicating left ventricular hypertrophy).

73 of LV hypertrophy (increased LV mass index [LVMI] of >=95 g/m2 for women or >=115 g/m2 for men) or m

74 with steeper gradients in low-biomarker/low-LVMI strata.

75 rrelation was found between RI and age, LVM, LVMI, and plasma parathormone concentration and was nega

76 ct was associated with a 2.6 g/m higher mean LVMI in men, and a 1.8 g/m higher mean LVMI in postmenop

77 mean LVMI in men, and a 1.8 g/m higher mean LVMI in postmenopausal women (p < 0.05).

78 here were no significant differences in mean LVMI between the stentless versus stented groups at base

79 load indices would be a better predictor of LVMI compared with SBP alone.

80 -43.8 to -123.6]) were better predictors of LVMI.

81 a standardized effect of more than 0.324 on LVMI; the largest standardized effect was 0.485, for %ID

82 : -2.54, 0.22) once the effect of mean BP on LVMI was adjusted for.

83 s, LV mass index (LVMI) decreased similarly (LVMI -6.3 +/- 2.2 g/m(2.7), -8.3 +/- 2.1 g/m(2.7), and -

84 The results showed that LVMI of patients treated with troglitazone was not stati

85 The LVMI decreased by 21% in the standard group and by 35% i

86 in ratio were positively associated with the LVMI in young males and females, respectively, independe

87 The strongest correlate of troponin was LVMI.

88 The primary end points were LVMI determined using cardiac magnetic resonance imaging

89 or diastolic OBP nor ABP was associated with LVMI.

90 e reliable and more strongly associated with LVMI.

91 BPV had a weak positive association with LVMI (10% increase in within-individual BP variance was

92 ictor of the combined endpoint compared with LVMI assessed with TTE (AIC, 127 vs 131).

93 e were moderately positively correlated with LVMI (r = 0.485 for %ID) and strongly positively correla

94 yrophosphate were moderately correlated with LVMI and strongly correlated, albeit in a small cohort,

95 inal fat correlated to a similar extent with LVMI.

96 to evaluate the association between Hct with LVMI and LVH.

97 ing could be an association between Hct with LVMI or LVH.

98 associated inversely and independently with LVMI.

99 n of each of the 4 quantitative metrics with LVMI, as a surrogate for amyloid burden.